1. Barriers to Oral Anticoagulant Use for Stroke Prevention in AF

2. Program Goals

3. Prevention of Stroke in Patients With AF

4. PINNACLE: Use of OAC

5. ESC Guideline Recommendations

6. Continued Use of Aspirin Is a Barrier to Effective Stroke Prevention

7. Main Advantages of NOACs Over Warfarin

8. NOACs vs Vitamin K Antagonists

9. Barriers to Optimal Anticoagulation

10. ENGAGE AF Patients at Risk for Falls Have a Greater Benefit in Terms of Lower Bleeding Risk of Edoxaban vs Warfarin

11. Who Is Being Treated?

12. CHA2DS2-VASc vs HAS- BLED

13. Barriers (cont): Creatinine Clearance

14. Renal Clearance and Dosage Adjustment

15. Barriers: Reversibility

16. Elective Interventional Procedures

17. Patient With AF and Requires PCI

18. WOEST

19. Dual vs Triple Therapy in AF Patients Requiring PCI

20. ESC Recommendations for Combination Therapy With Anticoagulants and Antiplatelets

21. ENTRUST- AF- PCI Edoxaban Treatment Versus Vitamin K Antagonist in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention

22. Barriers: Adherence

23. Adherence to OAC

24. Abbreviations

25. Abbreviations (cont)